Table 1.
Summary of outcomes reported in included records*
| 1st Author, Year | Type of Outcome Reported | |||||
|---|---|---|---|---|---|---|
| UTI, CAUTI, or FEUWD-UTI | IUC Utilization | Urine Cultures Ordered | Bacteriuria | Skin Complications | Other | |
| Peer Reviewed Published Manuscripts | ||||||
| Beeson, 2023 20 | CAUTI | X | UC | |||
| Cilluffo, 2022 21 | CAUTI | X | X | CS | ||
| Eckert, 2020 22 | CAUTI | X | ||||
| Jasperse, 2022 23 | UTI, CAUTI, FEUWD-UTI | X | X | LOH, ABX, MRC | ||
| Khosla, 2022 24 | CS | |||||
| Lem, 2022 25 | UTI, CAUTI, FEUWD-UTI | X | X | X | LOH, ABX, MRC | |
| Noval, 2022 26 | CAUTI | X | X | ABX | ||
| Rearigh, 2021 27 | CAUTI | X | X | |||
| Root, 2021 28 | X | CS | ||||
| Rose, 2021 29 | UC | |||||
| Tran, 2023 30 | CAUTI | X | X | CE, CS | ||
| Van Decker, 2021 31 | CAUTI | |||||
| Warren, 2020 32 | CAUTI | X | ||||
| Whitaker, 2023 33 | CAUTI | X | ||||
| Won, 2023 34 | CAUTI | X | X | |||
| Zavodnick, 2020 35 | CAUTI | X | CS | |||
| Peer Reviewed Abstracts | ||||||
| Auten, 2021 36 | CAUTI | |||||
| Beeson, 2018 37 | CAUTI | X | ||||
| Behrend, 2018 38 | CAUTI | X | UC, CE, CS | |||
| Cassone, 2022 39 | UC | |||||
| Chirca, 2018 40 | CAUTI | X | ||||
| Dublynn, 2019 41 | CAUTI | X | ||||
| Ecklund, 2020 42 | CAUTI | X | X | MRC, UC | ||
| Fields, 2019 43 | CAUTI | X | ||||
| Figueredo, 2020 44 | CAUTI | X | ||||
| Fritsch, 2019 45 | CAUTI | X | ||||
| Gentile, 2020 46 | CAUTI | X | ||||
| Goris, 2020 47 | CAUTI | X | ||||
| Gutzmirtl, 2019 48 | CAUTI | X | ||||
| Henry, 2019 49 | CAUTI | CE | ||||
| Hughes, 2020 50 | CAUTI | X | ||||
| Kelly, 2018 51 | CE | |||||
| Kelly, 2022 52 | CE | |||||
| Kuzow, 2019 53 | CAUTI | X | ||||
| Maydick-Youngberg, 2020 54 | X | |||||
| Mayes, 2020 55 | CAUTI | X | X | |||
| McRae, 2023 56 | UC, CS | |||||
| Mena Lora, 2020 57 | CAUTI | X | ||||
| Minor, 2022 58 | CAUTI | |||||
| Mueller, 2019 59 | CAUTI | X | ||||
| Nalbandian, 2022 60 | CAUTI | X | ||||
| Ohanian, 2022 61 | CAUTI | X | ||||
| Pavlovsky, 2020 62 | X | |||||
| Peters, 2021 63 | UTI | X | ||||
| Reeths, 2020 64 | X | |||||
| Riemenschneider, 2020 65 | X | |||||
| Srisatidnarakul, 2021 66 | CAUTI | X | ||||
| Sundhu, 2022 67 | LOH | |||||
| Taneja, 2023 68 | CS | |||||
| Wilkerson, 2020 69 | CAUTI | X | ||||
All studies are based in the United States except for Cilluffo et al. (Italy).
UTI, urinary tract infection not associated with an indwelling urinary catheter.
CAUTI, indwelling catheter-associated urinary tract infection.
FEUWD-UTI, female external urine wicking device-associated urinary tract infection.
IUC Utilization, indwelling urinary catheter utilization.
Urine Cultures Ordered, a test ordered by a clinician to determine the presence of infectious microorganisms in urine samples.
Bacteriuria, a positive culture of bacteria in urine (with or without symptoms of UTI, treated or untreated with antibiotics).
Skin Complications, inclusive of skin dermatitis, dermatologic allergic reaction, skin breakdown, pressure injuries.
Other: LOH, length of hospitalization; ABX, antibiotic use; MRC, mobility-related complications (e.g., deep vein thrombosis, falls); UC, urine collection; CE, cost-effectiveness; CS, comfort or patient/provider satisfaction.